[A17-24] Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2017
Commission awarded on 29.05.2017 by the Federal Joint Committee (G-BA).
Skin and hair
Adults with squamous-cell carcinoma of the head and neck and progression during/after platinum-based therapy
Indication of considerable added benefit for patients with progression up to 6 months after platinum-based therapy; added benefit not proven for progression occurring later
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.